Related Experiment Video
Updated: Jan 11, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Identification of five novel hub genes associated with interstitial lung disease in primary Sjögren's syndrome via
Zhou Junfei1, Zhao Zhen1, Qiang Fu2
1Department of Rheumatology, Henan Provincial People's Hospital, No. 7, Weiwu Road, Zhengzhou, 450000, China.
Background:
Interstitial lung disease (ILD) is a severe pulmonary complication of primary Sjögren's Syndrome (pSS), associated with significant morbidity and mortality. Identifying molecular markers and hub genes in pSS-associated ILD (pSS-ILD) may provide novel therapeutic targets.
Methods:
Peripheral blood mononuclear cells (PBMCs) were collected from pSS patients (n = 9), pSS-ILD patients (n = 6), and healthy controls (n = 15) for transcriptome sequencing. Differentially expressed genes (DEGs) were identified between pSS and controls (DEGs-SS) and between pSS-ILD and pSS groups (DEGs-SS-ILD). Overlapping DEGs were analyzed to identify hub genes using Cytohubba in Cytoscape. Functional enrichment, gene set enrichment analysis (GSEA), Spearman's correlation analysis, and immune infiltration analyses were performed. Potential drugs targeting hub genes were predicted, and molecular docking was conducted. Hub gene expression was validated using reverse transcription quantitative PCR (RT-qPCR).
Results:
A total of 932 DEGs-SS and 186 DEGs-SS-ILD were identified, with 78 overlapping genes. Five hub genes (IFIT2, IFIT3, LY6E, IFI27, and ISG15) were identified. IFIT2-IFIT3 and ISG15-LY6E showed strong expression correlations (correlation coefficient = 0.943, p < 0.05) and functional similarities. Immune infiltration analysis revealed a significant decrease in resting natural killer (NK) cells in pSS patients compared to controls, which was further reduced in pSS-ILD patients. Bisphenol A was identified as a potential therapeutic compound targeting IFIT3, IFIT2, LY6E, and IFI27, with high binding affinity (binding energy = -6.26 kJ/mol). RT-qPCR validation confirmed the differential expression of hub genes, consistent with bioinformatics findings.
Conclusion:
The hub genes IFIT2, IFIT3, LY6E, IFI27, and ISG15 represent potential biomarkers and therapeutic targets for pSS-ILD. These findings provide novel insights into the molecular mechanisms and potential treatments for pSS-ILD.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Single Nucleotide Polymorphisms-SNPs
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation

